Epitomics/Apexigen, US

In 2008, Simcere and Epitomics entered into a strategic partnership to jointly develop novel humanized rabbit anti-VEGF monoclonal antibody (SIM-BD0801). Under this agreement, Simcere owns 100% of the China right, and 50% of ex-China right.

© Copyright 2016 www.simcere.com All Rights Reserved.